// App-Quantinova.ai

TPS5101 : Carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following chemotherapy and androgen pathway inhibitors.

Researchers

Presenter

  • Guru Sonpavde

Principal Investigators

  • Frederick M. Schnell

  • Alan Cantor

  • Edward P Acosta

  • Isam-Eldin Eltoum

  • Graeme Bolger

  • Mollie DeShazo

  • Mansoor N. Saleh

  • Christopher G Wang

  • David James Mooney

  • Gurudatta Naik

Medical Centers

  • Georgia Cancer Spclsts PC, Atlanta, GA

  • The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, ALThe University of Alabama at Birmingham, School of Medicine, Birmingham, ALCentral Georgia Cancer Care, Macon, GA

  • The University of Alabama at Birmingham Medical Center, Birmingham, AL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic castration-resistant prostate cancer

  • Shingles

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • carfilzomib Intravenous

  • Docetaxel

  • Acyclovir

  • Androgen Tear

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • NCT02047253

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved